Abraxane Lung Cancer Approval Comes With Questionable Commercial Value

FDA clears Celgene’s Abraxane in lung cancer despite its lack of even a progression-free survival benefit. But the ease of approval is reassurance ahead of the release of melanoma results, with a PFS benefit, in November.